secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046176
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Therapeutics enters into $50M at-the-market equity offering facility with Jefferies
--------------------------------------------------------------------------------

- Agreement with Jefferies LLC allows sale of up to $50M of common stock from time to time.
- Agent compensation set at 3.0% of gross sales price per share sold.
- Company has no obligation to sell any shares under the Sales Agreement.
- Sales will be made under Company's existing shelf registration statement (Form S-3) filed same day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025046176/0000950170-25-046176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025046176/kytx-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer